Details for New Drug Application (NDA): 208088
✉ Email this page to a colleague
NDA 208088 describes TLANDO, which is a drug marketed by Verity and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the TLANDO profile page.
The generic ingredient in TLANDO is testosterone undecanoate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.
The generic ingredient in TLANDO is testosterone undecanoate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.
Summary for 208088
| Tradename: | TLANDO |
| Applicant: | Verity |
| Ingredient: | testosterone undecanoate |
| Patents: | 14 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208088
Generic Entry Date for 208088*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 208088
| Mechanism of Action | Androgen Receptor Agonists |
Suppliers and Packaging for NDA: 208088
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TLANDO | testosterone undecanoate | CAPSULE;ORAL | 208088 | NDA | Verity Pharmaceuticals Inc. | 74676-0112 | 74676-0112-2 | 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (74676-0112-2) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 112.5MG | ||||
| Approval Date: | Mar 28, 2022 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Nov 30, 2030 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED). | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Nov 30, 2030 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED). | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jan 8, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED). | ||||||||
Complete Access Available with Subscription
